On 2 March 2011 the Barcelona Court of Appeal handed down a judgment reversing a decision from Commercial Court n.4 of Barcelona, which rejected the patent owners’ ‘lis pendens‘ defence against a revocation action filed by L.A. and others based on lack of inventive step. In its judgment of 2 March 2011, the Court of…
The Court held that in order to decide that a patented invention is novel, it is not sufficient that the wording in the patent description is different from the wording in the prior art. The technical subject-matter of the prior art must be different. Moreover, it had to be assessed whether publicly accessible information could…
The Court addresses the issue of how to deal with a feature of a patent claim that was not originally disclosed, but the deletion of which would lead to a broadening of the scope of the claim and would thus not be admissible. The Court allowed that the feature remains in the claim, provided that…
The patentee (Claimant) filed a request for an interim injunction against the Defendant, ordering it to stop using the patented method, stop selling or importing Valsacor film coated tablets or any other products that would infringe the European patent, to seize the mentioned tablets, and to order Defendant to pay a penalty. The court rejected…
In a judgment issued on September 28, 2010, the Court of First Instance of Paris held that a dosage regime is effectively a method of treatment and is, as such, excluded from patentability in view of Article 53c of EPC 2000. In this particular case, the use of finasteride for the treatment of androgenic alopecia…
If a party decides to participate in another party’s challenge to a patent so it may share in the benefits of a victory, it may well be ordered to share the costs burden of losing. Actavis was therefore ordered to pay half of Eli Lilly’s costs of successfully defending the revocation actions brought by Dr…
The District Court of The Hague revoked Glaxo’s European Patent and Supplementary Protection Certificate (SPC) for an inhalable combination of fluticasone and salmeterol due to lack of inventive step. This decision is put in a pan-European perspective, with reference to the UK case law on inventive step, as well as the parallel English, German and…
The Supreme Court specifically addresses the issue of consideration of decisions issued in parallel cases before the European Patent Office or before national courts in EPC Member States and holds that such decisions may not be left unconsidered. A full summary of this case has been published on Kluwer IP Law.
The mere filing of an application for marketing authorization of a generic drug does not constitute an infringing activity., although of a preparatory nature as, aAlthough it is true that the filing of such an application may constitute the basis for the marketing of the drug, there still is the possibility that the eventual act…
The Supreme Court held that if someone exports goods from Germany and it is not proven that the same person imported them into Austria, there is no infringement of patent rights in Austria, even when the goods are assigned to be imported into Austria. In this particular case the Court of first instance carried out…
